BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 31499157)

  • 21. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
    Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
    Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
    Quaglino P; Maule M; Prince HM; Porcu P; Horwitz S; Duvic M; Talpur R; Vermeer M; Bagot M; Guitart J; Papadavid E; Sanches JA; Hodak E; Sugaya M; Berti E; Ortiz-Romero P; Pimpinelli N; Servitje O; Pileri A; Zinzani PL; Estrach T; Knobler R; Stadler R; Fierro MT; Alberti Violetti S; Amitay-Laish I; Antoniou C; Astrua C; Chaganti S; Child F; Combalia A; Fabbro S; Fava P; Grandi V; Jonak C; Martinez-Escala E; Kheterpal M; Kim EJ; McCormack C; Miyagaki T; Miyashiro D; Morris S; Muniesa C; Nikolaou V; Ognibene G; Onida F; Osella-Abate S; Porkert S; Postigo-Llorente C; Ram-Wolff C; Ribero S; Rogers K; Sanlorenzo M; Stranzenbach R; Spaccarelli N; Stevens A; Zugna D; Rook AH; Geskin LJ; Willemze R; Whittaker S; Hoppe R; Scarisbrick J; Kim Y
    Ann Oncol; 2017 Oct; 28(10):2517-2525. PubMed ID: 28961843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
    Miyashiro D; Sanches JA
    Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
    Benner MF; Jansen PM; Vermeer MH; Willemze R
    Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
    Liu KL; Tsai WC; Lee CH
    PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
    Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
    Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the Cutaneous Lymphoma International Prognostic Index in patients with early stage mycosis fungoides.
    Amorim GM; Corbellini JPN; Quintella DC; Cuzzi T; Ramos-E-Silva M
    An Bras Dermatol; 2018; 93(5):680-685. PubMed ID: 30156617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Racial disparity in mycosis fungoides: An analysis of 4495 cases from the US National Cancer Database.
    Su C; Nguyen KA; Bai HX; Cao Y; Tao Y; Xiao R; Karakousis G; Zhang PJ; Zhang G
    J Am Acad Dermatol; 2017 Sep; 77(3):497-502.e2. PubMed ID: 28645647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
    Kim YH; Bishop K; Varghese A; Hoppe RT
    Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
    Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
    Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides.
    Sun G; Berthelot C; Li Y; Glass DA; George D; Pandya A; Kurzrock R; Duvic M
    J Am Acad Dermatol; 2009 Feb; 60(2):231-5. PubMed ID: 19026464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
    Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography.
    Tsai EY; Taur A; Espinosa L; Quon A; Johnson D; Dick S; Chow S; Advani R; Warnke R; Kohler S; Hoppe RT; Kim YH
    Arch Dermatol; 2006 May; 142(5):577-84. PubMed ID: 16702495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Folliculotropism Does Not Affect Overall Survival in Mycosis Fungoides: Results from a Single-Center Cohort and Meta-Analysis.
    Giberson M; Mourad A; Gniadecki R
    Dermatology; 2017; 233(4):320-325. PubMed ID: 29169156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.